 |
|
|
|
|
Volume 1, Number 1, March 2000
POPULAR
TOPICPAPERMechanical strain-induced human vascular matrix synthesis: The role of angiotensin II
Adrian G Stanley, Hash Patel, Abigail L Knight, Bryan Williams Introduction: Reduced vascular compliance in patients with hypertension results from an increase
in extra-cellular matrix (ECM) protein deposition in blood vessels. At least two key factors,
namely mechanical strain and neurohumoral mediators, for example Angiotensin II (Ang II), promote
fibrogenesis within vessel walls; however potential interactions between these have not been
clearly defined. This work examined the direct effect of mechanical strain on matrix mRNA expression
and protein synthesis by human vascular smooth muscle (VSM) cells and identified the importance
of renin-angiotensin system (RAS) activation in stretch-induced matrix production.
Methods: Human VSM cells were exposed either to a cyclical mechanical strain regimen or to Ang II
in the presence or absence of the Ang II receptor (AT1 R) antagonist losartan or its more potent metabolite
EXP3174. Analysis of matrix mRNA expression (Northerns) and protein synthesis (ELISA) and cellular
AT1-receptor protein expression (Westerns) were determined.
Results: Ang II increased both collagen α1 (92%, SEM +/- 20%) mRNA expression and fibronectin (21%
+/- 6%) protein synthesis in static VSM cells compared with unstimulated controls. The effect
of Ang II was attenuated by antagonism of the AT1-receptor (AT1 R). Similarly, mechanical strain
induced an increase in both collagen α1 (102% +/- 30%) mRNA expression and fibronectin (50% +/-21%)
protein synthesis. Surprisingly, in the absence of exogenous Ang II, AT1-receptor blockade attenuated
this stretch-induced increase in matrix synthesis. Mechanical strain also induced an increase
in total cellular AT1-receptor protein (30.7% +/- 3.5%) compared with static cells.
Conclusion: Both mechanical strain and Ang II increased matrix gene expression and protein synthesis
by human VSM cells. The effect of strain was attenuated by AT1-receptor antagonism. Our results
further suggest that mechanical strain may sensitise human VSM cells to the fibrogenic actions
of Ang II, perhaps via upregulation of the AT1-receptor. JRAAS 2000;1:32-35. POPULAR
TOPICPAPERRat model for investigating ACTH-independent angiotensin-induced aldosterone secretion
Darren M Roesch,Ying Tian, Joseph G Verbalis, Kathryn Sandberg Study of the acute effects of angiotensin II (Ang II) on aldosterone secretion has been hindered
by the confounding influence of Ang II-induced adrenocorticotropic hormone (ACTH) secretion
on aldosterone secretion, and by the fact that when laboratory rats are fed standard laboratory
chows that are high in sodium, the adrenal is only minimally responsive to Ang II. In this study,
we report the development of a model of Ang II-induced aldosterone secretion in NaCl-deprived,
dexamethasone (DEX)-treated rats. This model allows the observation of (a) a high magnitude of
Ang II-induced aldosterone secretion, (b) a return of plasma aldosterone levels to baseline after
stimulation, and (c) aldosterone secretion without the potentially confounding influence of
ACTH stimulation. JRAAS 2000;1:36-39. POPULAR
TOPICPAPERReduction of resistance artery stiffness by treatment with the AT1-receptor antagonist losartan in essential hypertension
Jeong Bae Park, Hope D Intengan, Ernesto L Schiffrin In spontaneously hypertensive rats resistance artery structure, endothelial dysfunction and
geometry-independent wall stiffness were reduced by an angiotensin AT1-receptor antagonist.
In previous studies of human hypertension, interruption of the renin-angiotensin system corrected
small artery structure and endothelial dysfunction, whereas the β-blocker atenolol did not. We
hypothesized that the AT1R antagonist losartan, but not the β-blocker atenolol, would reduce stiffness
of gluteal subcutaneous small arteries in essential hypertensive patients. Seventeen untreated
mild essential hypertensive patients (47±2years; 75% male) were randomly assigned in double-blind
fashion to losartan or atenolol treatment for one year. Small, resistance size arteries were studied
on pressurized myographs. Blood pressure (mmHg) was reduced (p<0.01) from 145±4/101±2 and 147±6/98±2
to 128±4/86±2 and 131±3/84±1 by losartan and atenolol, respectively. The media/lumen ratio of small
arteries was unaffected by atenolol (8.3±0.3% before and 8.8±0.5% after treatment). In contrast,
losartan reduced media/lumen ratio from 8.4±0.4% to 6.7±0.3% (p<0.01). Whereas isobaric elastic
modulus was unaffected by either treatment, geometry-independent stiffness (slope of elastic
modulus vs. stress) was reduced from 9.7±1.2 to 6.1±0.9 (P<0.05) under losartan treatment, but was
unchanged by atenolol (8.2±1.3 to 7.8±0.6). In conclusion, treatment with losartan reduced stiffness
and structural alterations of subcutaneous resistance arteries of previously untreated essential
hypertensive patients, whereas atenolol failed to do so. JRAAS 2000;1:40-45. POPULAR
TOPICPAPERLosartan-induced apoptosis as a novel mechanism for the prevention of vascular lesion formation after injury
Jacinthe Lemay, Pavel Hamet, Denis deBlois Smooth muscle cell (SMC) apoptosis is transiently increased at the onset of the regression of aortic
hypertrophy in spontaneously hypertensive rats (SHR) treated with the angiotensin II AT1 antagonist
losartan. We postulated that losartan induction of SMC apoptosis contributes to suppression
of neointimal hyperplasia after vascular injury. Losartan or placebo treatment was initiated
two days before balloon injury in the SHR aorta. Compared with time-matched placebo, losartan
decreased neointimal cross-sectional area at Days 5 and 10 after injury by 50% and 64% respectively,
without affecting medial mass. At Day 10, losartan significantly decreased SMC number (by 56%)
in the neointima, but not in the media. DNA synthesis was significantly inhibited at Day 5 but not
at Day 10. Losartan significantly increased aortic DNA fragmentation by 2.6- and 4.1-fold, at
Days 5 and 10, respectively. In situ labeling of SMC with terminal deoxynucleotidyltransferase
revealed significant 61% and 68% increases in apoptotic SMC at Days 5 and 10 with losartan treatment,
predominantly in the neointima. Thus, losartan suppressed neointima formation in part by the
induction of SMC apoptosis, which may be dissociated from the inhibition of DNA synthesis. Therefore,
losartan-induced SMC apoptosis may be a potential therapeutic approach to control occlusive
vascular disorders. JRAAS 2000;1:46-50. POPULAR
TOPICEDITORIAL REVIEWThe past, present and future of hypertension management: a potential role for AT1-receptor antagonists
Norman K Hollenberg, Peter S Sever The benefits of effective antihypertensive treatment were established at least 40 years ago,
but despite the availability of more reliable and better-tolerated antihypertensive drugs,
the control of blood pressure remains poor in most patients. Long-term antihypertensive efficacy
requires treatment that combines reliable 24-hour reduction of blood pressure with good tolerability
to facilitate patient compliance. Treatment should also protect against target-organ damage.
As the majority of negative cardiovascular effects of angiotensin II are mediated through the
angiotensin II type 1 (AT1) receptor, specific blockade of this receptor is a rational approach
for achieving these ideals. Several AT1-receptor blockers have been developed that combine antihypertensive
efficacy and placebo-like tolerability - the latter being unique in the history of antihypertensive
therapy. In experimental animals these drugs prevent or reverse target organ damage in the heart,
the vasculature and the kidney. Ongoing large-scale outcome studies are now underway to establish
the benefits of AT1-receptor blockade beyond blood pressure control. JRAAS 2000;1:5-10. POPULAR
TOPICEDITORIAL REVIEWThe HOPE Study (Heart Outcomes Prevention Evaluation)
Peter Sleight The Heart Outcomes Prevention Evaluation (HOPE) study was designed to test the hypotheses that two preventive intervention strategies, namely angiotensin-converting enzyme (ACE) inhibition or vitamin E, would improve morbidity and mortality in patients at high risk of cardiovascular events compared with placebo. This review addresses the ACE inhibitor (ACE-I) (ramipril) arm of the study, both on the trial population as a whole, and on the large diabetic subgroup.
Patients were included in the study who were considered to be at high risk of future fatal or non-fatal cardiovascular events, by virtue of their age (>55 years), existing or previous cardiovascular disease, or diabetes. Diabetics had at least one other risk factor, either known vascular disease or other factors such as cigarette smoking, high cholesterol or hypertension. Ramipril or placebo was added to concomitant medication, which included, in a substantial proportion of patients, antihypertensive drugs (excluding ACE-I), lipid-lowering agents or aspirin. As a result, despite a history of hypertension in nearly 50% of patients, blood pressure (BP) at baseline was normal and the reduction in BP attributable to ramipril modest (a fall of 3-4 mmHg systolic BP and 1-2 mmHg diastolic).
The trial was stopped early on the advice of the Data Monitoring Committee because of convincing evidence of the benefit of ramipril treatment on the combined primary endpoint of cardiovascular death, non-fatal myocardial infarct (MI) and non-fatal stroke (14% vs. 17.8% on ramipril and placebo, respectively; relative risk reduction 22%, p<0.001). This comprised a risk reduction of 32% for stroke, 20% for MI, 26% for cardiovascular death and 16% for all-cause mortality, as well as a reduction in the risk of several other endpoints including heart failure and revascularisation procedures. The results among the 3577 diabetic subjects were even more striking, with a reduction of 25% in the combined primary endpoint.
This reduction in the combined endpoint and in particular the reduction in MI far exceeded that which would be expected from the modest fall in BP. Furthermore, a multiple regression analysis of the diabetic subgroup showed similar relative risk reductions even after allowing for the effects of the fall in BP. Possible explanations for the non BP-mediated benefits of ramipril include reduction of angiotensin II-induced intimal and vascular smooth muscle proliferation and possible plaque stabilisation.
The HOPE study results show that it is both safe and beneficial to lower BP that is already within the 'normal' range, particularly in patients with known vascular risk factors. This should greatly extend the use of ACE-I to a wider group of patients - not only those with left ventricular dysfunction, hypertension or diabetic microalbuminuria, but to the sort of high-risk patients who are currently given prophylactic treatment with aspirin. JRAAS 2000;1:18-20. POPULAR
TOPICEDITORIAL REVIEWAngiotensin II receptor blockers in chronic heart failure - Not as ELITE as expected!
Colin AJ Farquharson, Allan D Struthers As with many large-scale long-term outcome trials, more questions have been posed than answered
regarding the potential role of angiotensin II receptor blockers as first-line agents in chronic
heart failure. Given the present data, in patients with left ventricular systolic dysfunction,
ACE inhibitors must remain the treatment of choice, owing to the large body of data supporting their
use in this clinical syndrome. However, ARBs seems a reasonable alternative for renin-angiotensin
axis blockade in the significant number of heart failure patients who are genuinely intolerant
of ACE inhibitors.
The pendulum has now swung back in favour of ACE inhibition for chronic heart failure, although
one can only await with great expectation the results of the ongoing trials comparing not only angiotensin
II receptor blockers with ACE inhibitors but a combination of the two with regards tolerability
and survival. Whether this potentially useful class of drugs will ultimately become the cornerstone
of heart failure therapy in place of, or in addition to, ACE inhibitors is still in debate, but hopefully
we should not have to wait too long for the definitive answers. JRAAS 2000;1:21-22. POPULAR
TOPICEDITORIAL REVIEWRole of chymase on vascular proliferation
Mizuo Miyazaki, Shinji Takai In the normal state, vascular ACE regulates local angiotensin II formation and plays a crucial
role in the regulation of blood pressure, whereas chymase is stored in secretory granules in mast
cells and has no enzymatic effects such as angiotensin II-forming activity.47 Chymase has a maximal
activity immediately upon release into the extracellular matrix in vascular tissues after mast
cells have been activated by a strong stimulus such as experienced by catheter-injured and grafted
vessels.48 Therefore, chymase plays an important role in forming local angiotensin II when vascular
tissues are injured, and inhibition of chymase may be useful for preventing vascular proliferation
in grafted vessels and after PTCA (Figure 6). JRAAS 2000;1:23-26. POPULAR
TOPICEDITORIAL REVIEWACE inhibitors, angiotensin receptor antagonists and bradykinin
Michael Schachter Soon after the introduction of angiotensin-converting enzyme inhibitors (ACE-I), it became clear that the drugs were not specific for angiotensin I (Ang I), but also inhibited the breakdown of bradykinin (BK) and substance P. Moreover, the affinity of ACE for BK is much higher than for Ang I at both active sites of the enzyme. There has been great interest in trying to establish whether BK plays an important role in the therapeutic effects of ACE-I. It is now generally believed that BK is probably the major contributor to two of the side-effects characteristic of ACE-I - cough and angioedema.
BK has a variety of biological effects that can be categorised as pro-inflammatory (mostly involving the BK1 receptor subtype) and vasodilatory (involving predominantly BK2 receptors). Activation of endothelial BK2 receptors leads to increased synthesis of nitric oxide (NO) and release of prostacyclin; it is thus plausible that some of the vasodilator response to ACE inhibition may be mediated by increased generation of kinins and NO. There is also evidence that ACE-I may have a direct effect by preventing sequestration and inactivation of the BK2 receptor and by re-activating the receptor in BK-treated cells.
This paper reviews the currently available published data in both animal and human studies on the interactions of ACE and BK and the potential role of kinins in the response to ACE inhibition. JRAAS 2000;1:27-29. POPULAR
TOPICEDITORIAL REVIEWBlockade of the renin-angiotensin-aldosterone system and renal protection in diabetes mellitus
Hans-Henrik Parving A clinical diagnosis of diabetic nephropathy is made in patients with diabetes on the basis of persistent albuminuria (>300 mg/24-hour), the presence of diabetic retinopathy, and the absence of any clinical or laboratory evidence of other kidney or renal tract disease. This definition is valid in patients with either Type 1 or Type 2 diabetes. The clinical syndrome termed diabetic nephropathy is characterised by persistent albuminuria, early arterial blood pressure elevation, a relentless decline in glomerular filtration rate (GFR), and high risk of cardiovascular morbidity and mortality. Previous studies have found a cumulative incidence of diabetic nephropathy of 25–40% after diabetes duration of at least 25 years in both Type 1 and Type 2 diabetes. Diabetic nephropathy has become the leading cause (25–42%) of end-stage renal disease (ESRD) in Europe, Japan, and the United States. Unfortunately, the proportion of ESRD patients suffering from diabetes, particularly Type 2, is expected to rise significantly because the worldwide prevalence of diabetes is expected to double within the next 15 years, and because the individual diabetic patient lives longer and consequently has a greater risk of developing late complications including diabetic nephropathy.
This editorial reviews the evidence for the benefit of blockade of the renin-angiotensin-aldosterone system (RAAS) on the development and the progression of diabetic nephropathy. The renin-angiotensin-system plays an important role in the initiation and progression of diabetic kidney disease. Blockade of the RAAS reduces the progressive rise in albuminuria, diminishes the loss of glomerular filtration power, postpones end-stage renal failure and prolongs survival in patients with diabetic kidney disease. JRAAS 2000;1:30-31. POPULAR
TOPICEDITORIAL REVIEWNovel mechanisms linking angiotensin II and early atherogenesis
William B Strawn, Richard H Dean, Carlos M Ferrario We propose that Ang II exerts an as yet uncharacterized immunomodulatory effect on monocyte maturation,
differentiation, or extravasation, which may depend on the myelomonocytic phenotype. Since
the myelopoietic process originating at stem cells and culminating in release to the blood is at
least 6 days, it is conceivable that the observation of reduced monocyte CD11b expression two weeks
after completion of losartan treatment indicates a suppression of the CD11b phenotype in newly
released CD14+/CD45+ monocytes. Other studies employing suppression of AT1-receptors with
deoxy-oligonucleotides have reported effects on blood pressure that surpass those predicted
by the duration of the treatment.87 These data would suggest that it is possible to interrupt a stimulatory
signal by Ang II through a gene-related mechanism that in our experiments may reside in the mechanisms
that regulate myelopoiesis. While our knowledge of the role of Ang II in the regulation of monocyte
formation and function is incomplete, we have taken a first step in attempting to synthesize the
data described above into a comprehensive hypothesis for further evaluation of the factors that
initiate atherogenesis. Such effects may crucially contribute to the clinical benefit of AT1-receptor
antagonists, independent of depressor effects, and may represent a paradigm for novel, anti-inflammatory
actions by this class of drugs. JRAAS 2000;1:11-17. ABSTRACTAngiotensin receptor antagonists in the 21st century
C.I. Johnston, Baker Medical Research Institute, Melbourne, Australia JRAAS 2000;1:54. POPULAR
TOPICABSTRACTDifferential involvement of AT1-and AT2-receptors subtypes in the development of collateral vessels in chronic limb ischaemia in rats
Bernard I. Levy, HENRION Daniel, DURIEZ Micheline, BENESSIANO Joèlle, SILVESTRE Jean-Sebastien, deGASPARO Marc*, INSERM U141, IFR Circulation Paris 7; AP-HP Hôpital Lariboisière. 75475 Paris Cedex 10, France. * Novartis Pharma AG Switzerland JRAAS 2000;1:54. POPULAR
TOPICABSTRACTNovel signalling pathways contributing to AT1-induced vasoconstriction in human resistance arteries
A.D. Hughes, Clinical Pharmacology, NHLI, Imperial College of Science, Technology &. Medicine, St Mary`s Hospital, South Wharf Rd., London W2 INY, UK JRAAS 2000;1:54. POPULAR
TOPICABSTRACTIntracellular signalling events during stimulation of aldosterone biosynthesis by angiotensin II in adrenal glomerulosa cells
Alessandro M. Capponi, Division of Endocrinology and Diabetology, University Hospital, CH-1211 Geneva 14, Switzerland JRAAS 2000;1:54. POPULAR
TOPICABSTRACTAT1R antisense gene therapy protects normal rats from angiotensin II induced hypertension
M.J. Katovich, A.S. Pachori, H.W. Wang, C.H. Gelband, C.M. Ferrerio and M.K. Raizada. Departments of Physiology and Pharmacodynamics, University of Florida, Gainesville, Florida, 32610 JRAAS 2000;1:55. POPULAR
TOPICABSTRACTGene therapy for hypertension: recombinant adeno-associated virus vector delivery of angiotensin type 1 receptor antisense in hypertensive double transgenic mice
M. lan Phillips, Birgitta Kimura, Y. Clare Zhang, Curtis Sigmund*, Dagmara Mohuczy, Department of Physiology, University of Florida, Gainesville, FL and *Department of Internal Medicine, University of Iowa, Iowa City, IA 52242 JRAAS 2000;1:55. POPULAR
TOPICABSTRACTAT1R antisense gene therapy prevents medial thickening and balloon injury-induced neointimal hyperplasia in hypertension
M.L. Gardon, C.H. Gelband, M.J. Katovich, M.K. Raizada. Departments of Physiology and Pharmacodynamics, University of Florida, Colleges of Medicine and Pharmacy, Gainesville, FL 32610 JRAAS 2000;1:55. ABSTRACTTissue ACE in cardiovascular regulation; lessons from genetic manipulation
Kenneth E. Bernstein, Justin Cole, Dilek Ertoy, Jean Lin, Pierre Corvol, Emory Univ., Atlanta, GA JRAAS 2000;1:55. ABSTRACTPolymorphisms of the renin-angiotensin system. Their relevance to the development of cardiovascular disease
Pierre Corvol, Alexandre Persu, Anne-Paule Gimenez-Roqueplo and Xavier Jeunemaitre INSERM U36 - Collège de France - 3, rue d`Ulm - 75005 PARIS - FRANCE JRAAS 2000;1:56. POPULAR
TOPICABSTRACTHow important is aldosterone?
Allan D Struthers
Department of Clinical Pharmacology & Therapeutics, Ninewells Hospital, Dundee DDI 9SY JRAAS 2000;1:56. POPULAR
TOPICABSTRACTRevisiting aldosterone in congestive heart failure
Kari T. Weber, MD. Division of Cardiovascular Diseases. U. Tennessee, Memphis, USA JRAAS 2000;1:56. ABSTRACTAngiotensin II AT1-receptor blockade inhibits early atherogenesis in non-human primates
WB Strawn, MC Chappell, CM Ferrario. Wake Forest University School of Medicine, Winston-Salem, NC, USA JRAAS 2000;1:56. ABSTRACTRelationship between autoantibody against AT1-receptors and angiotensin in patients with refractory hypertension
Yu-Hua Liao, Yu-Miao Wei, Min Wang, Ji-Hua Dong, Zhao-Hui Wang Laboratory of Cardiovascular Immunology, Institute of Cardiology, Union Hospital, Tongji Medical University, Wuhan 430022, China JRAAS 2000;1:57. ABSTRACTOxLDL potentiates vascular Ang II-induced contractions via stimulation of rho-kinase - prevention by losartan
Jan Galle, Maria Görg, Alexander Mameghani, and Christoph Wanner. Dept. Med., Div. Nephrology, Univ. Würzburg, Germany JRAAS 2000;1:57. POPULAR
TOPICABSTRACTDifferential growth effects of ERK1/2 and p38 MAP kinase in Ang II-stimulated vascular smooth muscle cells from SHR
R.M. Touyz, G. He, X-H. Wu, M. El Mabrouk, E.L. Schiffrin. Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, Quebec. H2W IR7, Canada JRAAS 2000;1:57. ABSTRACTSynergy between angiotensin II and mechanical strain in matrix synthesis by human vascular smooth muscle cells
A.G. Stanley. H. Patel, B. Williams.
Cardiovascular Research Institute, University of Leicester, Faculty of Medicine and Biological Science, Leicester, United Kingdom JRAAS 2000;1:57. POPULAR
TOPICABSTRACTChymase inhibitor suppressed vascular proliferation in grafted veins
Shinji Takai1, Atsushi Yuda2, Denan Jin1, Masayoshi Nishimoto2, Shinjiro Sasaki2, Mizuo Miyazaki1
1Department of Pharmacology, and 2Thoracic and Cardiovascular Surgery, Osaka Medical College JRAAS 2000;1:58. ABSTRACTLosartan-induced apoptosis as a novel mechanism for the prevention of vascular lesion formation after injury
J. Lemay, P. Hamet and D. deBlois, CHUM Research Center, Montreal, Canada JRAAS 2000;1:58. ABSTRACTReduction of resistance artery stiffness by AT1 receptor antagonist treatment in essential hypertension
J.B. Park, H.D. Intengan, E.L. Schiffrin. Clinical Research Institute of Montreal, Montreal, 110 Pine Avenue West, Montreal, H2W IR7, Quebec, Canada JRAAS 2000;1:58. POPULAR
TOPICABSTRACTIrbesartan inhibits basal and angiotensin II, but not norepinephrine-induced, vascular protein synthesis in vivo
C Daigle, F MAC Martens, P Moreau, Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada JRAAS 2000;1:58. POPULAR
TOPICABSTRACTA comparison of angiotensin I-converting enzyme pathways in human blood vessels
Borland J.A.A.1; Chester A.H.1; Morrison K.A.1; Arnrani M.1; Wharton J.2; Yacoub, M.H.1
1 Department of Cardiothoracic Surgery, NHLI, Imperial College School of Medicine, Harefield Hospital, Harefield, Middlesex, UK. 2. Department of Histochemistry, Imperial College School of Medicine. Hammersmith Campus, Commonwealth Building, Du Cane Road, London, UK JRAAS 2000;1:59. ABSTRACTEffect of losartan on serum markers of endothelial activation in patients with Raynaud`s phenomenon and scleroderma - a pilot study
M Dziadzio1,3, C Denton1, D Abraham1, R Smith1, A Blann2, A Gabrielli3 and C Black1
1Centre for Rheumatotogy, Royal Free Hospital/University College, London, UK; 2Department of Medicine, City Hospital, Birmingham, UK; 3Clinica Medica, Università di Ancona, Italy JRAAS 2000;1:59. POPULAR
TOPICABSTRACTInhibition of centrally-mediated effects of angiotensin II by peripherally administered telmisartan
P.Gohlke, S. Weiss, A. Jansen, *W. Wienen, *J. Stangier, **W. Rascher, Th. Unger. Institute of Pharmacology, University of Kiel, *Boehringer Ingelheim, **Department of Paediatrics, University of Erlangen, Germany JRAAS 2000;1:59. POPULAR
TOPICABSTRACTLosartan-sensitive inhibition of vagal bradycardia by angiotensin II (Ang II) in the nucleus tractus solitarius (NTS) is mediated by nitric oxide
Sergey Kasparov and Julian F.R. Paton
Department of Physiology, School of Medical Sciences, University of Bristol, University Walk, Bristol, BS8 1TD JRAAS 2000;1:59. ABSTRACTThe effect of AII on apoptosis in human cardiomyocytes
C Wei, SW Downing, JS McLaughlin, Univ. of Maryland, Baltimore, MD, USA JRAAS 2000;1:60. ABSTRACTCardiac hypertrophy and remodelling in transgenic mice with myocardial specific overexpression of the AT1-receptor
P. Paradis, N. Dali-Youcef, F.W. Paradis, G. Thibault and M. Nemer. Laboratoire de développement et différenciation cardiaques. Institut de recherches cliniques de Montréal, Montréal, Quebec, Canada JRAAS 2000;1:60. POPULAR
TOPICABSTRACTEnhanced regional AT2-receptor and protein kinase C expression during cardioprotection induced by AT1-receptor blockade after reperfused canine myocardial infarction
B.I. Jugdutt, Y. Xu, M. Balghith, R. Moudgil, D.W. O`Brien, V. Menon, University of Alberta, Edmonton, Alberta, CANADA JRAAS 2000;1:60. ABSTRACTCaspase-3 activation and selective induction of apoptosis in non-cardiomyocytes by valsartan in spontaneously hypertensive rats
deBlois D, Der Sarkissian S, Tea B-S, Hamet P, CHUM Research Center, Montreal, CANADA JRAAS 2000;1:60. ABSTRACTEvidences for pathological involvement of human chymase in atherogenesis
Urata H, Uehara Y, Koga T, Okamoto T, Fujimi K, Hoshino T, ldeishi M, Arakawa K.
Dept. Internal Medicine, Fukuoka University, 7-45-7 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan JRAAS 2000;1:61. POPULAR
TOPICABSTRACTEvidence for cross-talk between angiotensin II receptors and α2-autoreceptors in mouse isolated atria
S.L. Cox. V. Schelb & K. Starke
Department of Pharmacology, University of Freiburg, Freiburg, Germany JRAAS 2000;1:61. POPULAR
TOPICABSTRACTAngiotensin II stimulates activation of the transcription factor NF-κB and expression of cyclooxygenase-2 in rat cardiac fibroblasts
Nicole Scheuren, Martina Jakobs, Georg Ertl, Winfried Schorb, Department of Medicine, University of Würzburg, Germany JRAAS 2000;1:61. ABSTRACTCardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C after ischaemia-reperfusion in the dog
B.I. Jugdutt, Y. Xu, D.W. O`Brien, University of Alberta, Edmonton, Alberta, CANADA JRAAS 2000;1:61. POPULAR
TOPICABSTRACTPerindopril and losartan inhibit the stimulatory effect of high levels of glucose on the expression of angiotensinogen gene and hypertrophy in kidney proximal tubular cells
JSD Chan1*, SL Zhang1, C To1, X Chen1, JG Filepl, SS Tang2, JR Ingelfinger2 and S Carrière3. 1Univ. of Montreal, Maisonneuve-Rosemont Hosp., Montreal, Canada HIT 2M4, 2Harvard Med. School, Mass. Gen. Hosp., Boston, USA, 3Servier-Amèrique, Laval, Canada JRAAS 2000;1:62. POPULAR
TOPICABSTRACTATII-Inducible PDGF A-Chain gene expression is p42/44 ERK- and Egr-1-dependent and mediated via the ATII type 1 but not type 2 receptor: induction antagonized by NO
Levon M. Khachigian, Fiona Day, Louise Rafty, Colin N. Chesterman. Centre for Thrombosis and Vascular Research, The University of New South Wales, and Department of Haematology, Prince of Wales Hospital, Sydney, Australia L.Khachigian@unsw.edu.au JRAAS 2000;1:62. ABSTRACTPre-treatment with losartan blunts nicardipine-induced increase in sympathetic activation and heart rate
David Calhoun and Sutao Zhu, University of Alabama at Birmingham, 520 ZRB, 703 South 19th Street, Birmingham, AL 35294-0007, USA JRAAS 2000;1:62. ABSTRACTAbsence of central effects of losartan: usefulness for individuals involved in critical occupations
AN NICHOLSON, D P ROBERTS, BARBARA M STONE & CLAIRE TURNER
Centre for Human Sciences, Defence Evaluation and Research Agency, Farnborough, Hants. GU14 0LX JRAAS 2000;1:62. POPULAR
TOPICABSTRACTACE inhibitors and angiotensin II antagonist in the treatment of progressive renal disease
H-H. Parving, Steno Diabetes Center, DK-2820 Gentofte, Denmark JRAAS 2000;1:63. ABSTRACTIntervention strategies for microalbuminuria: the role of angiotensin II antagonists, including dual blockade with ACE-I and a receptor blocker
Carl Erik Mogensen, Medical Dept M Aarhus Kommunehospital, Aarhus University Hospital, DK-8000 Aarhus, Denmark JRAAS 2000;1:63. POPULAR
TOPICABSTRACTTargeting TGF-ß overexpression in fibrotic disease: maximising the antifibrotic action of AII blockade
Wayne A. Border, M.D., Professor of Medicine, Fibrosis Research Laboratory, 391 Chipeta Way, Suite E, Salt Lake City. Utah 84108, USA JRAAS 2000;1:63. POPULAR
TOPICABSTRACTLosartan reduces sympathetic (SNS) outflow from the brain of rats with chronic renal failure (CRF)
Vito M. Campese, Shaohua Ye, Rex H. Troung, Michael Gamburd, Eissa Amani. Department of Medicine, Univ. of Southern California, Los Angeles, CA, USA JRAAS 2000;1:63. POPULAR
TOPICABSTRACTFailure of tubulo-vascular signalling by NO in the hypertensive kidney: restoration by candesartan
Welch, W.J. and Wilcox, C.S.
Division of Nephrology and Hypertension, Georgetown University Medical Center, Washington, DC, 20007, USA JRAAS 2000;1:64. ABSTRACTRenoprotective effect (antihypertensive and antiproteinuric) of losartan in renal transplant (RT) recipients
JM Campistol, P Iñigo, N Esforzado, D del Castillo, MD Navarro, R Saracho, F Anaya, Oppenheimer, Renal Transplant Unit, Hospital Clinic, University of Barcelona, Spain JRAAS 2000;1:64. POPULAR
TOPICABSTRACTTargets or goals - should they be achieved and if so, how?
Stepben MacMahon, Institute for International Health, University of Sydney, Australia JRAAS 2000;1:64. POPULAR
TOPICABSTRACTTargets or goals - should they be achieved and if so, how?
Joël Ménard, Public Health Department, UFR Broussais-Hôtel Dieu, Paris, France JRAAS 2000;1:64. POPULAR
TOPICABSTRACTPartial inactivation of the renin-angiotensin-aldosterone system by conventional doses of angiotensin-converting enzyme inhibitors in chronic heart failure
Thierry H. Le Jemtel, Pugazhendi Vijayaraman, Pierre-Vladimir Ennezat, and Edmund H. Sonnenblick; Albert Einstein College of Medicine; Bronx, New York, USA JRAAS 2000;1:65. POPULAR
TOPICABSTRACTShould angiotensin II antagonists be used with or without ACE inhibitors in heart failure?
JN Cohn, University of Minnesota Medical School, Minneapolis, Minnesota, USA JRAAS 2000;1:65. POPULAR
TOPICABSTRACTPartial ACE inhibition in chronic heart failure
P.Vijayaraman, U.Jorde, P.Ennezat, V.Suryadevara, J.Lisker, E.Sonnenblick, T.H. LeJemtel. Albert Einstein College of Medicine, Bronx, New York, USA JRAAS 2000;1:65. POPULAR
TOPICABSTRACTPretreatment with losartan has cardiovascular protection in a rat model of ischaemia-reperfusion
Bo-qing Zhu, Yi-ping Sun, Richard E. Sievers, Amanda EM. Browne, Randall J. Lee, Tony M. Chou, Kanu Chatterjee, William W. Parmley. University of California San Francisco, San Francisco, California, USA JRAAS 2000;1:65. POPULAR
TOPICABSTRACTMyocardial protection by preconditioning of heart with losartan, an AT1-receptor blocker
Nilanjana Maulik, PhD, Motoaki Sato, MD, Richard M. Engelman, MD and Dipak K. Das, PhD. Cardiovascular Research Center, University of Connecticut School of Medicine, Farmington, CT 06030-1110, USA JRAAS 2000;1:66. POPULAR
TOPICABSTRACTAbsence of tissue-bound angiotensin-converting enzyme results in an impaired cardiac function after myocardial infarction
W.M. Aartsen1, J.J.M. Debets1, P.J.A. Leenders1, M.J.A.P. Daemen2 and J.F.M. Smits1. Depts of Pharmacology1 and Pathology2, CARIM, Universiteit Maastricht, The Netherlands JRAAS 2000;1:66. ABSTRACTOxidative stress, renin-angiotensin system and heart failure; b) effects of AII type 1 blockade by losartan
Neelam Khaper and Pawan K. Singal
Institute of Cardiovascular Sciences, St. Boniface Gen. Hosp. Research Centre, University of Manitoba, Winnipeg, Canada JRAAS 2000;1:66. ABSTRACTChronic AT1-receptor blockade attenuates haemodynamic deterioration in a dog model of progressive heart failure
Moe GW, Naik G, Konig A, Yi X, Jugdutt, B. University of Toronto, Toronto and University of Alberta, Edmonton, Canada JRAAS 2000;1:66. ABSTRACTAngiotensin II antagonist prevents electrical remodelling in atrial fibrillation
Hideko Nakashima. Koichiro Kumagai, Hidenori Urata, Naoki Gondo, Munehito Ideishi, Kikuo Arakawa, Fukuoka University, Fukuoka, Japan JRAAS 2000;1:67. POPULAR
TOPICABSTRACTAngiotensin II antagonism vs. ACE inhibition in the therapy of retinal disease
M.E. Cooper, Department of Medicine, University of Melbourne, Repatriation Campus, Heidelberg West, Victoria, Australia. JRAAS 2000;1:67. ABSTRACTTissue protection - new data from experimental models
Thomas Unger, MD
Institute of Pharmacology, University of Kiel, Kiel, Germany JRAAS 2000;1:67. ABSTRACTThe intra-uterine environment programs angiotensin II receptor-mediated hypertension in later life
A.R. Trowern, R.C. Sherman, C, Bertram, R. Dunn, D. Gardner, S.C. Langley-Evans & C.B. Whorwood: Endocrinology & Metabolism Unit, University Medicine, Southampton General Hospital, Tremona Rd, Southampton SO16 6YD, UK JRAAS 2000;1:67. ABSTRACTLosartan therapy reduces thrombin-receptor agonist-induced platelet aggregation
PJ Levy, C Yunis, J Owen, KB Brosnihan, S Kivlighn, CM Ferrario
Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157, USA JRAAS 2000;1:68. ABSTRACTCombination of non-hypotensive doses of valsartan & enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction
Marc de Gasparo, Patrick Hess, Jean-Paul Clozel, Novartis Pharma AG, Basel, Switzerland, Actelion, Allschwil, Switzerland JRAAS 2000;1:68. POPULAR
TOPICABSTRACTRenin-angiotensin system (RAS) and cold-induced hypertension (CIH)
Z. Sun and R. Cade
Departments of Physiology & Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA JRAAS 2000;1:68. ABSTRACTDo propranolol and losartan have a direct proapoptotic effect on vascular myocells?
M. Buemi, A. Alegra, D. Marino, G. Di Pasquale, C. Aloisi, M.A. Medici, A. Romeo, M. Senatore, N. Frisina, F. Corica JRAAS 2000;1:70. POPULAR
TOPICABSTRACTEffect of angiotensin II receptor blocker on angiotensin II stimulated proliferation of cultured rat aortic smooth muscle cells
Fang Xiao, J.R. Puddefoot, AJ. Ogedegbe, G.P. Vinson Molecular and Cellular Biology, Division of Biomedical Sciences, Queen Mary and Westfield College, London El 4NS, UK JRAAS 2000;1:70. ABSTRACTComparison of the responses of foetal and maternal arteries to angiotensin II and losartan
E.R. Lumbers, J.R. McMullen, B.D. Hegarty, K.J. Gibson School of Physiology & Pharmacology, University of New South Wales, SYDNEY 2052, Australia JRAAS 2000;1:70. ABSTRACTCross talking between angiotensin II and nitric oxide in rabbit clitoral cavernosum
Jong Kwan Park*, Sung Zoo Kim, Young Beom Jeong*, Young Gon Kim* and Kyung Woo Cho, Department of Urology* and Physiology, Chonbuk National University, Medical School, 560-180, Chonju, South Korea JRAAS 2000;1:70. ABSTRACTRole of renin-angiotensin-system in rabbit corpus cavernosum smooth muscle
Young Beom Jeong*, Jong Kwan Park*, Sung Zoo Kim, Suhn Hee Kim, Kyung Woo Cho, Departments of Urology* and Physiology, Chonbuk National University Medical School, Chonju, 560-180, Korea JRAAS 2000;1:71. POPULAR
TOPICABSTRACTEffect of losartan on phosphatidylcholine membranes: comparison with a less biologically active molecule
E. Theodoropoulou1, D. Marsh1, M. Koufaki2, J. Matsoukas3, 1Max-Planck-lnstitut für biophysikalische Chemie, 37070 Göttingen, Germany. 2N.H.R.F., Vas. Constantinou 48, 11635 Athens, Greece. 3University of Patras, 26500 Patras, Greece JRAAS 2000;1:71. ABSTRACTLosartan inhibits uptake of oxidised LDL in human monocyte-derived macrophages from patients with familial hypercholesterolemia
T. Hayek, R. Heinrich, E. Sakhnini, M. Aviram and S. Keidar Lipid Research Unit, Rappaport Institute, Technion, Haifa, Israel JRAAS 2000;1:71. ABSTRACTContribution of nitric oxide to the effect of losartan
Kiyo Inoue, Hikaru Nishimura, Jiro Kubota and Yasushi Kitaura
Third Department of Internal Medicine, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan JRAAS 2000;1:71. POPULAR
TOPICABSTRACTThe effects of irbesartan on vascular neointima hyperplasia and smooth muscle cells apoptosis after balloon injury
Guo-Xiang He, Geng Wang and Xun-Min Cheng. Dept of Cardiology, Southwest Hospital, Third Military Medical University, Chongqing 400038, P. R. China JRAAS 2000;1:72. ABSTRACTAT1 antagonist normalises resistance artery structure and endothelial function in essential hypertension
J.B.Park, H.D.lntengán, E.L.Schiffrin. Clinical Research Institute of Montreal, Montreal, 110 Pine Avenue West, Montreal, Quebec, H2W 1R7, Canada JRAAS 2000;1:72. ABSTRACTAT1-mediated activation of c-Src-dependent signalling is augmented in vascular smooth muscle cells from SHR
R.M. Touyz, X-H. Wu, G. He, E.L. Schiffrin. Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, Quebec. H2W IR7, Canada JRAAS 2000;1:72. ABSTRACTCaspase-dependent cell death during regression of aortic hypertrophy in SHR treated with losartan
deBlois D., Marchand E., CHUM Research Center, Montreal, Canada JRAAS 2000;1:72. ABSTRACTAT1-receptor blockade of AT1-receptor prevents post-ischaemic leukocyte-endothelium interaction and microvascular dysfunction
Kumiko Akiyoshi, Tadafumi Akimitsu, Syuji Ishida, Naohiko Takahashi, Masahide Hara, Tetsunori Saikawa, Toshiie Sakata. Department of internal medicine I, Oita medical university JRAAS 2000;1:73. POPULAR
TOPICABSTRACTStudy of two AT1 antagonists: irbesartan and losartan in cholesterol-fed rabbits
Ganado. P., M. Sanz, E. Ruiz and T. Tejerina. Dept of Pharmacology, F. f Medicine, Complutense University, 28040 Madrid, Spain JRAAS 2000;1:73. ABSTRACTPharmacology of angiotensin-II receptors in the thoracic aorta vasa vasorum microcirculation
X. Shao, A. Chainey, G. E. Plante, Departments of Medicine and Pharmacology, University of Sherbrooke, Canada JRAAS 2000;1:73. ABSTRACTThoracic aorta endothelial dysfunction in hypertensive rat: role of angiotensin
G.E. Plante, S. Lehoux, A. Larouche. Departments of Medicine and Pharmacology, University of Sherbrooke, Canada JRAAS 2000;1:73. ABSTRACTTelmisartan - influence on endothelial dysfunction in hypertensive patients
J. Petrović, Z. Popović, D. Petrović, D. Djurić, Health Center Studenica, Kraljevo, Cardiovascular Research Center, Dedinje Cardiovascular Institute, Belgrade Yugoslavia JRAAS 2000;1:74. ABSTRACTLosartan reduces collagen content and intimal thickening of illiac arteries after balloon injury in rabbits
Zhu Jianhua, Gao Danchen, Department of Cardiology, First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China, 310003 JRAAS 2000;1:74. ABSTRACTAngiotensin II activates JUN-kinase in cultured human endothelial cells
A. Gudmundsdottir1, K. Magnusdottir1, H. Halldorsson1, G. Thorgeirsson2 1Department of Pharmacology, University of Iceland, Reykjavík, 2Department of Medicine, Landspítalinn, University Hospital Reykjavík, Iceland JRAAS 2000;1:74. ABSTRACTEffects of AT1 and AT2-antagonism on Ang II induced atherosclerosis and abdominal aortic aneurysms
Lisa Cassis and Alan Daugherty, College of Pharmacy and Gill Heart Institute, University of Kentucky, Lexington, KY, USA JRAAS 2000;1:74. ABSTRACTEvidence for AT1-and AT2-receptors in isolated human subcutaneous resistance arteries
H Ytterberg, L Edvinsson
Department of Internal Medicine, University Hospital, S-22158 Lund, Sweden JRAAS 2000;1:75. ABSTRACTEvidence for a cyclic AMP (cAMP)-dependent pathways in AT1-receptor in human omental arteries
H Ytterberg, L Edvinsson
Department for Internal Medicine, University Hospital, S-22185 Lund, Sweden JRAAS 2000;1:75. POPULAR
TOPICABSTRACTBasilar artery remodelling in the genetically hypertensive (GH) rat; effects of NOS inhibition and treatment with valsartan and enalapril
J.M. Ledingham and R. Laverty, Department of Pharmacology, School of Medical Sciences, University of Otago, Dunedin, New Zealand JRAAS 2000;1:75. ABSTRACTMyometrial and subcutaneous vessel responses to angiotensin II and phenylephrine in pre-eclampsia
Wimalasundera R†*, Regan L†, Thorn S*, Hughes A*- Imperial College School of Medicine and Technology at St Mary`s, *Clinical Pharmacology and †Obstetrics & Gynaecology, London JRAAS 2000;1:75. ABSTRACTAngiotensin II & phenylephrine responses in myometrial & subcutaneous resistance vessels in pre-eclampsia, normal pregnancy and the non-pregnant state
Wimalasundera R†*, Regan L†, Thom S*, Hughes A*- Imperial College School of Medicine and Technology at St Mary`s, *Clinical Pharmacology and †Obstetrics & Gynaecology, London JRAAS 2000;1:76. ABSTRACTAngiotensin II-induced contraction in human isolated resistance arteries is dependent on calcium influx and insensitive to pertussis toxin and PKC inhibition
R.S. Garcha, P.S. Sever, A.D. Hughes
Clinical Pharmacology, NHLI, Imperial College of Science, Technology & Medicine, London W2 1NY, U.K. JRAAS 2000;1:76. ABSTRACTChymase inhibitor decreases aortic cholesterol deposition in high cholesterol-fed hamster
Yoshinari Uehara, Hidenori Urata, Munehito Ideishi, Kikuo Arakawa
Department of Internal Medicine, Fukuoka University, Fukuoka, Japan JRAAS 2000;1:76. ABSTRACTRenin-angiotensin-aldosterone system gene polymorphisms and hypertension in diabetic and non-diabetic Hong Kong Chinese
Thomas GN1, Tomlinson B1, Chan JCN1,2, Ding BG1, Cockram CS2 and Critchley JAJH1. Divisions of Clinical Pharmacology1 and Endocrinology2, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong SAR JRAAS 2000;1:76. ABSTRACTComparative analysis of enalapril-diazepam interaction on myocardial contractility: study in isolated hearts of rats
Ribeiro J.M, Neves H.J., Gomes OM.
Felicio Rocho Hospital and São Francisco de Assis Cardiovascular Foundation, São F. de Assis Hospital, Belo Horizonte, MG, Brazil JRAAS 2000;1:77. ABSTRACTEffects of specific inhibitors of the vasoactive substances released by the ischemic reperfused liver on the isolated rat heart
I. Alterman, E. Hochhauser, A. Weinbroum, T. Krasnov, A. Raz, B.A. Vidne FMRC, Rabin Med. Center, Petah Tikva, Tel Aviv Univ., lsrael JRAAS 2000;1:77. ABSTRACTEndothelin but not angiotensin II, participates in the mechanism of endothelial dysfunction in guinea-pig hearts
Michal Maczewski, Andrzej Beresewicz
Department of Clinical Physiology, Medical Centre of Postgraduate Education, ul. Marymoncka 99, 01-813 Warsaw, Poland JRAAS 2000;1:77. ABSTRACTTransforming growth factor ß-induced differentiation fibroblasts to myofibroblasts is accompanied by an angiotensin-converting enzyme activity
P. Lijnen, V. Petrov, R. Fagard. Hypertension Unit, University of Leuven, (KULeuven), Belgium JRAAS 2000;1:77. ABSTRACTAngiotensin ll-Binding, Fibroblast and Collagen Alterations in Myocardial Infarcted Rat Hearts
A.B.Bikhazi, M.E.EI-Sabban, G.N.EI-Zein, and K.A.Hassan. Faculty of Medicine, American University of Beirut, Beirut, Lebanon JRAAS 2000;1:78. ABSTRACTComparison of Losartan, Enalapril and Their Combination in Preventing Ventricular Remodeling after Myocardial Infarction in Rats
Yuejin Yang, Pei Zhang, Yingmao Ruan, Laifeng Song, Yongli Li, Yanwen Zhou, Jilin Chen, Zaijia Chen, Yishu Xu. Fu Wai Heart Hospital, Beijing, China JRAAS 2000;1:78. ABSTRACTOxidative stress, renin-angiotensin system and heart failure: a) effects of ACE inhibition by captopril
Pawan K. Singal and Neelam Khaper
Institute of Cardiovascular Sciences, St. Boniface Gen. Hosp. Research Centre, University of Manitoba, Winnipeg, Canada JRAAS 2000;1:78. ABSTRACTApoptosis in response to AT1 receptor ligand binding is enhanced in cardiomyocytes isolated from adult spontaneously hypertensive rats
MA. Fortuño, S. Ravassa, G. Zalba, A. Fortuño, J. Díez Vascular Pathophysiology Unit School of Medicine. University of Navarra, Spain JRAAS 2000;1:78. ABSTRACTEffect of AT1 receptor blockade on TGF- ß signaling in heart failure due to myocardial infarction in rat
Jianming Hao and lan M.C. Dixon. Laboratory of Molecular Cardiology, Institute of Cardiovascular Sciences, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada JRAAS 2000;1:79. ABSTRACTLosartan versus angiotensin II in programmed cell death
V. Voicu, M. Hinescu, R. Alexandrescu, A. Pociu, Z. Marculescu. Univ. Med. & Army Med. Res. Ctr., Bucharest, Romania JRAAS 2000;1:79. ABSTRACTAngiotensin II receptor blockade prevents force reduction by CHF in rat cardiac trabeculae
HEDJ ter Keurs, AW Davidoff, University of Calgary, Calgary, Alberta, Canada JRAAS 2000;1:79. ABSTRACTAngiotensin II receptor blockade preserves rate dependence of force in trabeculae from CHF rat
AW Davidoff, HEDJ ter Keurs, University of Calgary, Calgary, Alberta, Canada JRAAS 2000;1:79. ABSTRACTLosartan and ischemia-reperfusion injury in isolated working rat hearts
TACCARDI A.A., DI NAPOLI P., SPINA R., MAGGI A., VIANALE G., STUPPIA L., PALKA G., BARSOTTI A.
Dep. Clinical Sciences and Bioimaging, Lab. Exp. Cardiology University of Chieti, Italy JRAAS 2000;1:80. ABSTRACTThe changing of matrix metalloproteinase-1 gene expression in rat with myocardial infarct and the effect of intervention
Hongwei Li MD,PhD, Aimin Wang MD,PhD, Luhua Shen MD, Fusheng Gu MD, Hui Peng MD. Beijing Friendship Hospital, Capital University of Medical Sciences, Beijing 100050, PR.China JRAAS 2000;1:80. ABSTRACTEffect of losartan and combined perindopril on left ventricular function after AMI in rats
Hongwei Li MD,PhD. LH. Shen MD, FSH. Gu MD, H. Peng MD, DB. Li MD Department of Cardiovascular, Beijing Friendship Hospital, Beijing 100050, P.R.China JRAAS 2000;1:80. ABSTRACTAngiotensin II AT1 receptors stimulate protein synthesis in human heart fibroblasts via a Ca2+ sensitive PKC-dependent tyrosine kinase pathway
Mingyan Hou, Emil Pantev, Sebastian Möller, David Erfinge & Lars Edvinsson1. Division of Experiment Vascular Research, Department of Internal Medicine, Lund University Hospital, Lund, Sweden JRAAS 2000;1:80. ABSTRACTStructural and functional cardioprotection at long-term antihypertensive treatment based on enalapril
O.J. Zharinov, N.D. Oryshchyn, O.B. Detsyk, V.O. Bobrov. Cardiology Department, Kyiv Medical Academy of Postgraduate Education, Nar. Opolchenia Str. 5, Kiev 252151, Ukraine JRAAS 2000;1:81. ABSTRACTBeneficial effects of combined therapy with ACE-inhibitors and AT1-receptor antagonist eprosartan in patients with severe chronic heart failure
B.Gremmler, M.Kunert, H.Schleiting, L.J.UIbricht. Cardiol. Dept. of Marien Hospital, Bottrop, Germany JRAAS 2000;1:81. ABSTRACTIrbesartan efficacy and tolerability in essential and renal hypertension
V. Ivan*, A. Schiller**, M. Turcan* Cardiology Department*, Nephrology Department**,
University Hospital Timisoara, Romania JRAAS 2000;1:81. ABSTRACTEffects of candesartan cilexetil on symptoms and neurohormones in patients with congestive heart failure
Mitrovic V, Alegria E, Dabrowski M, Dukat A, Edler K, George M, Kiowski W, Lenz K, Marks DS, Miric M, Seferovic P, Spinar J, Willenbrock R. Klinik der Max-Planck Gesellschaft, Bad Nauheim, Germany JRAAS 2000;1:81. ABSTRACTInfluence of Losartan on Ventricular Arrhythmia and Heart Rate Variability in patients with Congestive Heart Failure
Yu. N. Belenkov, Ia.A. Orlova, V.Yu. Mareyev, F.T. Ageev, A.A. Skvortsov,
Cardiology Research Center, Moscow, Russia JRAAS 2000;1:82. ABSTRACTFrequency of angiotensin-converting enzyme genotypes in hypertensive patients with left ventricular hypertrophy
BMY Cheung, RYH Leung, CP Lau
Department of Medicine, University of Hong Kong, Hong Kong JRAAS 2000;1:82. POPULAR
TOPICABSTRACTDoes the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study
P. Di Pasquale*, A. Tuttolomondo**, V. Bucca*, S. Scalzo*, S. Cannizzaro*, A. Giubilato*, A. Ortoleva**, G. Follone**, S. Paterna**, G.Licata**.
* Department of Cardiology, G.F. Ingrassia Hospital, Corso Calatafimi n. 1002, Palermo, Italy. ** Department of Internal Medicine, University of Palermo, Piazza delle Cliniche n. 2, Palermo JRAAS 2000;1:82. ABSTRACTInfluence of captopril on immunologic parameters in dilated cardiomyopathy
S.G. Shuratova. prof., A.Sh. Rustemova, A.K. Dzhusipov, prof., A.K. Zhumanova
Kazakh Scientific Research Institute of Cardiology, Aiteke Bi 120, 480083, Almaty, Kazakhstan JRAAS 2000;1:82. ABSTRACTEfficacy of irbesartan versus enalapril on left ventricular mass reduction and diastolic function in hypertensive subjects
S. Villatico Campbell, V. Rizzo, F. Di Maio, F. Petretto, R. Perilli, A. Gurgo, *D. Tallarico. I and *Vl Clinica Medica, "La Sapienza" University of Rome, Via del Policlinico 155, Rome, Italy JRAAS 2000;1:83. ABSTRACTLeft ventricular geometry and atrial volumes changes after antihypertensive therapy with losartan and fosinopril
S.Villatico Campbell, V. Rizzo, F. Di Maio, F. Petretto R. Perilli, A. Gurgo, *D. Tallarico. I and *VI Clinica Medica, "La Sapienza" University of Rome, Italy, via del Policlinico 155, Rome JRAAS 2000;1:83. ABSTRACTEffects of losartan and captopril on systolic and diastolic function and excercise tolerance in congestive heart failure patients: comparative study
V. Mareev, F. Ageev, A. Ovchinikov, A. Skvortsov, Yu. Belenkov
Cardiology Research Center, Moscow, Russia JRAAS 2000;1:83. POPULAR
TOPICABSTRACTRegression of thickness of cardiac structures - losartan versus lisinopril
Moreira, C.S.; Alcântara, P.; Varela, G.; Ramalhinho, V.; Braz-Nogueira, J
Department of Medicine. Hosp S. Maria, Lisbon, Portugal JRAAS 2000;1:83. ABSTRACTThe Renoprotective Effect of Losartan in Experimental Chronic Renal Failure-Prevention of Mesangial Hypertrophy in Glomeruli
Eliahou HE, Avinoach I, Shahmurov M, Shahar C, Ben-David A, Matas
Z. Zimlichman R. Departments of Medicine, Biochemistry and Pathology, Edith Wolfson Medical Center, Holon, lsrael, 58100. JRAAS 2000;1:84. ABSTRACTTI: The role bFGF & ET played in the damage in SHR and how Benazepril & Losartan protected the renal function
AU: Wang Xiaodan; Zhen Quifu; Yu Xiajun; Zeng Qiang
AD: Chinese PLA General Hospital, Beijing, P.R. of China JRAAS 2000;1:84. ABSTRACTAngiotensin II type 1 receptor blockade in experimental acute renal failure
Z. Miloradović, Ð. Jovović, M. Jerkić, N. Mihailović-Stanojević, G. Stošić
lnstitute for Medical Research, Dr. Subotića 4, 1129 Belgrade, Yugoslavia JRAAS 2000;1:84. ABSTRACTIs the antialbuminuric effect of angiotensin II antagonists in essential hypertension mediated by interference with TGF-ß ?
Concepción Laviades, Nerea Varo, Javier Díez. San Jorge General Hospital, Huesca, and University Clinic, School of Medicine, University of Navarra, Pamplona, Spain JRAAS 2000;1:84. POPULAR
TOPICABSTRACTEnalaprilat ameliorates cyclosporin nephrotoxicity in humans via direct tubulointerstitial effects
DA Vesey1, DW Johnson1, HJ Saunders2, WQi2, Michael J Field2, CA Pollock2
Department of Renal Medicine, Princess Alexandra Hospital, Brisbane, and Department of Medicine2, University of Sydney at Royal North Shore Hospital, Sydney, Australia JRAAS 2000;1:85. ABSTRACTAntitoxidant effects of Losartan (L) and protection of renal Tubulointerstitial Lesions (TIL) in Hyperoxaluric Rats (HoxR)
Leon Ferder, MD1, Jorge Toblli, MD2, Elena MV de Cavanagh PhD3, Cesar Fraga, PhD3. Margarita Angerosa, PhD2, Felipe MD1. 1Lab. Nephr. Exp, ININCA, Buenos Aires, Argentina. 2Lab. Exp. Med., Hosp. Alemán. 3Physchem., FFyB-UBA. JRAAS 2000;1:85. POPULAR
TOPICABSTRACTRegulation of NaHCO3 Reabsorption by Ang II: The Role of the Membrane Potential
Eitan Gross, Depts. of Urology and Physiology & Biophysics, CWRU and VA Med CTR, Cleveland, OH, USA JRAAS 2000;1:85. ABSTRACTEprosartan suppresses TGFß and PAI-1 gene expression in rats with renal failure
David P. Brooks, Lisa C. Contino, Nicholas J. Laping, Barbara A. Olson and Victoria Y Wong. Department of renal Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA, USA JRAAS 2000;1:85. ABSTRACTEffects of losartan and proteases on tubulointerstitial fibrosis, ages and MDA levels in UUO model in rat
1Šebeková K, 2Schinzel R, 2Munch G, 3Galbavý Š, 4Blažicek P, 2Heidland A. 1IPCM, 3Commenius Univ. and 4Military Hospital, Bratislava; Slovakia; 2Univ. Würzburg, Germany JRAAS 2000;1:86. ABSTRACTAT1 receptor mediated uptake of angiotensin II in renal cortex and medulla
M. Grima, C. Ingert, J. Steger, M. Barthelmebs and JL. Imbs
Institut de Pharmacologie, Faculté de Médecine, and Service d`Hypertension et Maladies Vasculaires, Hôpitaux Universitaires de Strasbourg, France JRAAS 2000;1:86. ABSTRACTRenal tissue angiotensin II regulation
M. Grima, C. Ingert, C. Coquard, M. Barthelmebs and JL. lmbs
Institut de Pharmacologie, Faculté de Médecine, and Service d`Hypertension et Maladies Vasculaires, Hôpitaux Universitaires de Strasbourg, France JRAAS 2000;1:86. ABSTRACTAngiotensin II receptor type I blockade reduces cyclosporine A nephrotoxicity via downregulation of apoptotic genes in vivo
Ihab Wahba, M.D., William Bennett, M.D., Takeshi Andoh, Ph.D.
Affiliation: Oregon Health Sciences University, Portland, OR JRAAS 2000;1:86. ABSTRACTEffect of angiotensin II receptor antagonist, losartan on glycoxidation in patients with essential hypertension
M. Yamakado, H. Shimomura, E. Maehata, Department of Health Care, Mitsui Memorial Hospital, 1 Kanda Izumicho, Chiyoda-ku, Tokyo 101-0024, Japan JRAAS 2000;1:87. ABSTRACTIn vivo effect of angiotensin II receptor blockade on glomerular TGF-ß1 gene expression in diabetic rats
NS Nahman Jr, UY Bhatt, TJ Sferra, J Kronenberger, A Johnson, C Williams Depts of Medicine and Pediatrics, Ohio State University, Columbus, OH, USA JRAAS 2000;1:87. ABSTRACTEffect of long-term losartan administration on renal haemodynamics and function in hypertensive patients
S. Paterna, R. Scaglione, R. Costa, G. Parrinello, A. Bova, V. Accardo Palumbo, A.Tuttolomondo and G. Licata
Department of Internal Medicine University of Palermo. P.zza delle Cliniche 2 90127 Palermo, Sicily JRAAS 2000;1:87. POPULAR
TOPICABSTRACTCompare the effects of losartan and enalapril on renal RAS in SHR and SHR-DM
Liu Xiaoping, Guo Jizhen, Gao Pingjin, Zhu Dingliang
Shanghai Institute of Hypertension, Rui-jin Hospital,
Shanghai Second Medical University JRAAS 2000;1:87. ABSTRACTLosartan normalizes the plasma levels of TGF-ß1 in a random, crossover study (Losartan vs. Amlodipine) in renal transplant patients treated with CsA
P. Iñigo, JM. Campistol, S. Lario, M. Bescós, F. Oppenheimer. Renal Transplant Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain JRAAS 2000;1:88. ABSTRACTEffects on intrarenal-hemodynamics of losartan vs. amlodipine in a cross-over study in renal transplant patients
JM. Campistol, P. Iñigo, C. Piera, F. Oppenheimer. Renal Transplant Unit, and Nuclear Medicine Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain JRAAS 2000;1:88. ABSTRACTCyclosporine/tacrolimus alter renin-angiotensin system (ras) in mouse medullary thick ascending limb cultured cells
MS Wu, CW Yang, HM Yu, YC Ko, CT Huang, CC Huang
Division of Nephrology, Chang-Gung Memorial Hospital, Taipei, Taiwan JRAAS 2000;1:88. ABSTRACTRenal effects of angiotensin II receptor subtype 1 and 2-selective ligands injected into the paraventricular nucleus of conscious rats
1Luiz Antonio de Arruda Camargo, 2Wilson Abrão Saad
1Dept. Fisiologia e Patologia, Fac. Odontologia, UNESP, Araraquara, SP, Brazil. 2Dept. Odontologia, Univ. Taubaté UNITAU, Taubaté, SP, Brazil JRAAS 2000;1:88. ABSTRACTAngiotensin II does not mediate the pressor response to PGD2 (icv)
1Kadekaro, M., 1Kershenovich, A., 1Terrell M.L., 2Summy-Long, J.Y. 1The University of Texas Medical Branch at Galveston, 301 University Blvd., Galveston TX 77551-0517 and 2Pennsylvania State University College of Medicine, 500 University Dr., Hershey, PA 17033 JRAAS 2000;1:89. POPULAR
TOPICABSTRACTOn the memory enhancing effect of ACE inhibitor and AT1 receptor antagonist in inhibitory shock avoidance task
S. K. Kulkarni, V. Raghavendra and K. Chopra
Pharmacology Division, University Institute of Pharmaceutical Sciences,
Panjab University, Chandigarh-14, India JRAAS 2000;1:89. ABSTRACTAT1 receptor antagonism enhances angiotensin-II facilitated carrageenan-induced paw edema
S.K. Kulkarni and V. Raghavendra
Pharmacology Division, University Institute of Pharmaceutical Sciences,
Panjab University, Chandigarh-14, India JRAAS 2000;1:89. ABSTRACTCellular immune functions and the effect of losartan treatment in primary hypertension
1Sönmez A., 1Koç B., 2Ksa Ü., 1Eyileten T., 1Üçkaya G., 1Öktenil Ç., 1Bulucu F., 1Aslan H., 1Kocabalkan F.
Gülhane Medical Faculty, Departments of 1Internal Medicine and 2Biochemistry, Etlik, Ankara TURKEY JRAAS 2000;1:89. ABSTRACTEffect of losartan on the proliferation of normal and scleroderma dermal and lung fibroblasts and collagen type 1 production
M Dziadzio1,2, D Abraham1, A Gabrielli2 and CM Black1,
1Centre for Rheumatology, Royal Free Hospital and University College, London and 2Istituto di Clinica Medica, Ematologia ed Immunologia, Universita di Ancona, Italy JRAAS 2000;1:90. ABSTRACTFootshocks (fs) produces hypotension in losartan treated rats: role of kinins and nitric oxide
Israel A., Sosa B., Cierco, M and Gutierrez Cl. Universidad Central de Venezuela and Universidad Francisco de Miranda y Universisdad Centro Occidental Lisandro Alvarado. Venezuela JRAAS 2000;1:90. ABSTRACTThe Effects of Captopril and Losartan on the Fibrinolytic System in Rat
Li. Zhi-shan; Jia Ru-yi
Dept. of Cardiology Zhong Shan Hospital, 180 Feng Lin Road, Shanghai, 200032, P.R. China JRAAS 2000;1:90. ABSTRACTMechanical Regulation of IGF-I, IGFBP-2 and IGFBP-4 through Angiotensin II in Bladder Smooth Muscle Cells
B.CHAQOUR, I. Tamura, and E. J. Macarak
University of Pennsylvania, School of Dental Medicine/Histol. 4001 Spruce ST. Philadelphia, PA 19104, U.S.A. JRAAS 2000;1:90. ABSTRACTEffect of angiotensin II AT1 receptor blockade (losartan) on fibroproliferation in a rat model of post transplant bronchiolitis obliterans
A. MacLean, M. Suga, S. Fischer, M. Liu, and S. Keshavjee
Thoracic Surgery Research Laboratory, Toronto General Hospital, Toronto, Ontario, Canada JRAAS 2000;1:91. ABSTRACTStrain differences in the behavioural effects of losartan in mice
P. R. Gard, School of Pharmacy and Biomolecular Sciences, University of Brighton, UK JRAAS 2000;1:91. ABSTRACTMolecular cloning of atypical gerbil angiotensin receptor type 1 which show reduced losartan binding affinity
K.-L. Hoe, R. Moriuchi, and J.M. Saavedra
Section on Pharmacology, National Institute of Mental Health, 9000 Rockville Pike, Bldg. 10, Rm. 2D57, Bethesda, MD, USA JRAAS 2000;1:91. ABSTRACTPre- and postsynaptic activities of four ATl-antagonists in SHR
A. Dendorfer, W. Raasch, K. Tempel, and P. Dominiak
Inst. of exp. and clin. Pharmacol. and Toxicol., Med. University Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany JRAAS 2000;1:91. ABSTRACTThe combination of candesartan and ramipril increases antihypertensive and antihypertrophic effects in SHR compared to monotreatment of substances
W. Raasch, A. Gieselberg, S. Schwartz, and P. Dominiak
Institute of exp. & clin. Pharmacology and Toxicology,
Medical University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany JRAAS 2000;1:92. ABSTRACTCandesartan, ramipril or a combination of both improve the insulin sensitivity in spontaneously hypertensive rats
W. Raasch, C. Schwartz, J. Krützfeldt*, H. Klein*, P. Dominiak
Institute of exp. & clin. Pharmacology, and Toxicology, *Medical Clinic I Medical University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany JRAAS 2000;1:92. ABSTRACTLosartan and captopril modify some in vitro immune functions of normal and uraemic peripheral blood mononuclear cells
Luciak M., Zbróg Z., Bartnicki P., Majewska E., Baj Z.: 2nd Dept. of Internal Med., and Dept. of Pathophysiology, WAM, Lódz, Poland JRAAS 2000;1:92. POPULAR
TOPICABSTRACTLosartan suppresses the AGE-BSA induced activation of PKC, overexpression of TGF-ß1 and enhanced AT1 receptor protein in human tubule and pig LLCPK1 cells
G. Xiang, R. Schinzel, K. Sebekova and A. Heidland
Dept. of Internal Medicine, Institute of Physiological Chemistry, Univ. of Wuerzburg, Germany; Institute of Preventive and Clinical Medicine, Bratislava, Slovakia JRAAS 2000;1:92. ABSTRACTA two-state receptor model for the interaction between angiotensin type 1 receptors and non-peptide antagonists
P.M.L. Vanderheyden, F.L.P. Fierens, I. Verheijen, J.P. De Backer, and G. Vauquelin
Department of Molecular and Biochemical Pharmacology, Free University of Brussels (VUB), Paardenstraat 65, B-1640 Sint-Genesius Rode, Belgium JRAAS 2000;1:93. ABSTRACTAn involvement of AT2 receptor in the antithrombotic effect of losartan in rats
Ewa Chabielska, Iwona Kucharewicz, Tomasz Matys, Dariusz Pawlak, Wlodzimierz Buczko, Department of Pharmacodynamics, Medical University, Bialystok, Poland JRAAS 2000;1:93. POPULAR
TOPICABSTRACTThe inferior olive of the rat brain: a model for AT2 receptor signaling
Garrido, M.R. and Israel, A. School of Pharmacy, Universidad Central de Venezuela, Apartado Postal 50176, Sabana Grande 1050, Caracas, Venezuela. E-mail: chary@goplay.com JRAAS 2000;1:93. ABSTRACTFibrinolytic function in diuretic-induced volume depletion: effects of AT1-receptor blockade
K. Lottermoser, H.J. Hertfelder*, B. Weißer, H. Vetter, R. Düsing
Medizinische Universitäts-Poliklinik and *Institut für Experimentelle Hämatologie, Bonn, Germany JRAAS 2000;1:93. POPULAR
TOPICABSTRACTHypertensive response and tolerance during exercise test after treatment with Angiotensin II Antagonist
H. Grassos, G. Konstantellos, N. Kouris, M. Sifaki, E. Kalkandi, S. Benetatos, D. Babalis
Cardiology Dept, Western Attica General Hospital, Athens, Greece. JRAAS 2000;1:94. ABSTRACTThe role of angiotensin-(l-7) in the antithrombotic action of losartan
Kucharewicz I, Chabielska E, Pawlak B, Matys T, Buczko W.
Department of Pharmacodynamics, Medical University, Bialystok, Poland JRAAS 2000;1:94. ABSTRACTInsulin sensitivity is influenced by the degree of salt consumption: the role of the renin angiotensin system
P.O. Prada, L.N.S. Furukawa, J.C. Heimann, M.S. Dolnikoff. Laboratory of Experimental Hypertension. University of São Paulo, School of Medicine, São Paulo, Brazil JRAAS 2000;1:94. POPULAR
TOPICABSTRACTAn open-label, cross-over study to evaluate the pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan
J Stangier1, CAPF Su1, G Deichsel2, G Heinzel1, W Roth1
1Boehringer Ingelheim Pharma KG, Biberach; 2Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany JRAAS 2000;1:94. ABSTRACTLack of effect of telmisartan on the pharmacokinetics and safety of ibuprofen
J Stangier1, CAPF Su1, W Roth1, A Fraunhofer2, W Tetzloff2
1Boehringer Ingelheim Pharma KG, Biberach; 2IPHAR Institute for Clinic Pharmacology GmbH, Höhenkirchen-Siegertsbrunn, Germany JRAAS 2000;1:95. ABSTRACTEffect of telmisartan on steady-state pharmacodynamics and pharmacokinetics of warfarin in healthy subjects
J Stangier1, CAPF Su1, W Roth1, JJ van Lier2, MGC Hendriks2, FAE Sollie2, PJG Cornelissen3, JHG Jonkman2
1Boehringer Ingelheim Pharma KG, Biberach, Germany; 2Pharma Bio-Research Zuidlaren, The Netherlands; 3Boehringer Ingelheim BV, Alkmaar, The Netherlands JRAAS 2000;1:95. POPULAR
TOPICABSTRACTMultiple-dose pharmacokinetics of telmisartan and hydrochlorothiazide following concurrent administration in normal subjects
J Stangier1, C-L Young2, R Dubiel2, W Roth1
1Boehringer Ingelheim Pharma KG, Biberach, Germany; 2Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA JRAAS 2000;1:95. ABSTRACTEffect of multiple-dose telmisartan 120 mg on steady-state digoxin pharmacokinetics in healthy volunteers
J Stangier1, CAPF Su1, MGC Hendriks1, JJ van Lier2, FAE Sollie2, JHG Jonkman2
1Boehringer Ingelheim Pharma KG, Biberach, Germany; 2Pharma Bio-Research International BV, Zuidlaren, The Netherlands JRAAS 2000;1:95. ABSTRACTSafety and efficacy of telmisartan versus enalapril in moderate renal failure patients with mild-to-moderate hypertension
T Hannedouche, 1J Chanard, 2 B Baumelou3
1Service de Néphrologie, Hôpital Civil, Strasbourg; 2Service de Néphrologie, Hôpital Maison-Blanche, Reims; 3Clinical Research Unit, Boehringer Ingelheim, Reims, France JRAAS 2000;1:96. ABSTRACTNitric oxide in blood plasma of hypertensive patients under treatment with irbesartan
Radchenko V.V., Svyshchenko E.P., Mishchenko L.A., Kotsuruba A.V.
Institute of Cardiology, Kyiv, Ukraine JRAAS 2000;1:96. ABSTRACTDeoxycorticosterone (DOCA) suppresses the preventive effects of losartan in L-NAME hypertension
MC de Gracia, R Wangensteen, J Sainz, C García del Río, F Vargas, A Osuna.
Departamento de Fisiología y Servicio de Nefrología, U. Experimental V. de las Nieves, Granada, Spain JRAAS 2000;1:96. ABSTRACTScreening for Angiotensin II Receptor Antagonists in human urine by HPLC with photometric detection
L. González, R.M. Alonso and R.M. Jiménez
Departamento de Química Analítica, Facultad de Ciencias, Universidad del Pais Vasco, Apdo. 644,48080, Bilbao JRAAS 2000;1:96. ABSTRACTHuman erythropoietin production is influenced by angiotensin II
1S. Freudenthaler. 2C. H. Gleiter; 1Dept. of Nephrology and Rheumatology, University of Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany, 2Dept. of Clinical Pharmacology, University of Tübingen, Wilhelmstr. 56, 72074 Tübingen JRAAS 2000;1:97. ABSTRACTComparative effects of angiotensin II AT-1 type receptor antagonists in vitro on human platelet activation
A. López-Farré, J.I. Guerra-Cuesta, L. Rico, J. Farré, M. Montón, R. Ayala, A.M. Jiménez, P. Marcos, J. Gómez, A. Nuñez, S. Casado. Cardiovascular Research and Hypertension Laboratory, Fundación Jiménez Díaz, Madrid, Spain. JRAAS 2000;1:97. ABSTRACTAngiotensin II receptor blockade with telmisartan in preclinical and clinical studies
H. Nolly, A. Nolly, M. Nolly
Lab. of Experimental Hypertension, School of Medicine, Mendoza, Argentina JRAAS 2000;1:97. POPULAR
TOPICABSTRACTLosartan treatment influence on the morning rise of blood pressure, catecholamines and insulin level
O.Yarinkina, E.Svyshchenko, L. Mchitarian, E. Kasimirko
Department of Hypertension, Institute of Cardiology, Kyiv, Ukraine JRAAS 2000;1:97. POPULAR
TOPICABSTRACTSerum Uric Acid and Cardiovascular Mortality: NHANES I Epidemiological Follow-up 1971-1992
Jing Fang, Michael H. Alderman. Department of Epidemiology & Social Medicine, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA JRAAS 2000;1:98. ABSTRACTThe antihypertensive efficacy and safety of irbesartan alone or associated for the treatment of essential hypertension in community hospitals of Catalonia
J. Sobrino. A. Felip, J. Plana, J. Soler, L. Ribera, M.J. Adrián, J. Módol, A. Mínguez, J. Esqué, M. Pladevall, L. Comas, M. Casas, J. Closas, J. Roma, A. Coca. Hypertension Research Foundation of the Catalan Community Hospitals (FEHTACC), Barcelona, Spain JRAAS 2000;1:98. ABSTRACTValsartan treatment in mild to moderate essential hypertensive patients: structural and abpm relationships
Massimo Crippa, Raffaella Costa, llaria Notaristefano, Ermanna Chiari, Raffaele Fariello. Internal Medicine & Cardiology Department, Spedali Civili, Brescia, Italy JRAAS 2000;1:98. ABSTRACTCandesartan, ABPM & relationship between structural and functional parameters in essential hypertensives
Raffaella Costa, Massimo Crippa, Ilaria Notaristefano, Nicola Pagnoni, Ermanna Chiari, Raffaele Fariello
Dpt Intern Med & Cardiol, Spedali Civili, Brescia, Italy JRAAS 2000;1:98. ABSTRACTDoes antihypertensive therapy with angiotensin converting enzyme inhibitor or angiotensin AT1 receptor antagonist affect haemostatic markers in patients with essential hypertension?
F Li-Saw-Hee, AD Blann and GYH Lip. Haemostasis, Thrombosis and Vascular Biology Unit, University Dept. of Medicine, City Hospital, Birmingham, U.K. JRAAS 2000;1:99. ABSTRACTArterial hypertension management with enalapril and losartan combination
E.Nesukay, G.Andryeyeva, E.Krot, L.Ardelyanu, Ukrainian Institute of Cardiology, Kiev, Ukraine JRAAS 2000;1:99. ABSTRACTEffects of enalapril and irbesartan on left ventricular mass and microalbuminuria in hypertensive patients
M.Mettimano, F.Pichetti, L.Fazzari, A.Migneco, A.FIex, MR.Montebelli, L.Savi
Hypertension Center, Catholic University of Rome, Italy JRAAS 2000;1:99. ABSTRACTComparison of valsartan and enalapril in regression of left ventricular hypertrophy
Sanem Nalbantgil, Hasan Yilmaz, Cemil Gürün, Mehdi Zoghi, Istemi Nalbantgil, Remzi Önder. Ege University Medical School, lzmir, Turkey JRAAS 2000;1:99. POPULAR
TOPICABSTRACTComparative evaluation of the antihypertensive efficacy of enalapril and losartan at ISH
S. Nedogoda
Medical Academy, pl. Pavshih Bortzov 1, Volgograd, Russia, 400066 JRAAS 2000;1:100. POPULAR
TOPICABSTRACTThe effects of the first dose of losartan or enalapril in old patients
S. Nedogoda
Medical Academy, pl. Pavshih Bortzov 1, Volgograd, Russia, 400066 JRAAS 2000;1:100. ABSTRACTEffects of irbesartan and ramipril on internal carotid artery blood flow in elderly hypertensives
A. V. Yagensky, V. A. Nahrebetsky
Lutsk City Hospital, Lutsk, Ukraine JRAAS 2000;1:100. ABSTRACTReplacement of angiotensin converting enzyme inhibition by angiotensin II blockade in congestive heart failure (REPLACE project)
PHJM Dunselman1 and the REPLACE Project Investigators 1Working Group on Cardiovascular Research, Breda, The Netherlands JRAAS 2000;1:100. POPULAR
TOPICABSTRACTValsartan is effective in elderly patients with systolic hypertension
M.P. Bedigian, J. Neutel, M. Kozinn, N. Gunderson, E. Krinsky, D. Purkayastha. Novartis Pharmaceuticals, East Hanover, NJ, USA JRAAS 2000;1:101. ABSTRACTAmbulatory assessment of once-daily candesartan cilexetil versus enalapril in patients with hypertension
A. Himmelmann, S. Keinänen-Kiukaanniemi, A. Wester, J. Redon, R. Asmar, T. Hedner for the EffECT study group. Sahlgrenska University Hospital, Sweden, University of Oulu, Finland, Midden Twente Ziekenhuis, The Netherlands, University of Valencia, Spain, Institut de Recherche et Formation Cardiovasculaire, France JRAAS 2000;1:101. ABSTRACTCandesartan cilexetil/HCTZ in primary hypertension insufficiently controlled on monotherapy - a comparison with losartan/HCTZ
KP Öhman1,2, H Milon3, K Valnes4
AstraZeneca AB1, Dept. of Medicine and Care, Faculty of Health Sciences, University Hospital, Linköping, Sweden2; Service de Cardiologie, Hopital de la Croix Rousse, Lyon Cedex, France3; Stovner, Oslo, Norway4. JRAAS 2000;1:101. ABSTRACTSymptomatology and quality of life assessment in hypertensive patients following a change in treatment regimen
EJ Stewart, JD Bentkover, FH Frech, QD Doan, MP Bedigian
Innovative Health Solutions, 1330 Beacon Street, Suite 316, Brookline, MA 02446, USA JRAAS 2000;1:101. ABSTRACTIndomethacin does not modify irbesartan hypotensive effects in salt-sensitive black hypertensives on low and high salt diets
A. Damasceno, P. Caupers, A. Santos, J. Polónia. Faculty of Medicine Eduardo Mondlane of Maputo, Mozambique & Clinical Pharmacology Unit, Faculty of Medicine, Porto, Portugal JRAAS 2000;1:102. ABSTRACTIrbesartan shifts circadian blood pressure rhythm from non-dipper to dipper in salt-sensitive black hypertensives on high salt diet
J. Polönia, P. Caupers, A. Santos, A. Damasceno. Faculty of Medicine Eduardo Mondlane of Maputo, Mozambique & Clinical Pharmacol Unit, Faculty Medicine of Porto, Portugal JRAAS 2000;1:102. ABSTRACTValsartan in combination with hydrochlorothiazide reduces the incidence of diuretic-induced hypokalemia: an integrated analysis of clinical data
H. Black1, A. Graff2, R. Glazer3, J. Pincus3. 1Rush-Presbyterian-St. Luke`s Medical Center, Chicago, IL; 2Fort Lauderdale, FL; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA JRAAS 2000;1:102. POPULAR
TOPICABSTRACTComparative antihypertensive efficacy and safety of losartan and valsartan in hypertensive patients
V. H. Monterroso1, V. R. Chavez2, D. R. Vogel3, G. J. Aroca Martinez4, L.H. Garcia4, J.H.B. Cuevas5, T. Dumortier6, A.M.G. Bunt7, R.D. Smith7
1Hospital San Juan de Dios, Ciudad, Guatemala; 2Hospital FAP Comandante Juan Benavides Doric, Lima, Peru; 3Hospital Regional Espanol, Buenos Aires, Argentina; 4Clinica Renal de la Costa, Columbia; 5Morones Prieto, Monterrey, Mexico; 6MSD CBARDS, Brussels, Belgium; 7Merck & Co. Inc., Whitehouse Station, New Jersey, USA JRAAS 2000;1:102. ABSTRACTAngiotensin II antagonists for hypertension: are there differences? A meta-analysis meta-analyzed
T.J.Cleophas, Albert Schweitzer Hospital, Dordrecht; M.G.Niemeyer, Martini Hospital, Groningen; A.H.Zwinderman, Academic Hospital, Leiden, The Netherlands JRAAS 2000;1:103. ABSTRACTReplacement of ACE-inhibitors by AII-receptor antagonists in hypertensive patients with type II diabetes mellitus; metabolic consequences
Jan van der Meulen1, Johan P.van der Sluijs1, Ton J.Cleophas1, Aeilko H.Zwinderman2. 1Merwede Hospital, Dordrecht, 2University Hospital, Leiden, the Netherlands JRAAS 2000;1:103. ABSTRACTUnstable angina pectoris and the effect of losartan, lisinopril, and hydrochlorothiazide treatment in preventing nitrate tolerance
Rehber H., Üstü Y., Baykal Y., Aslan H., Öktenli Ç., Kocabalkan F.
Gülhane Medical Faculty, Department of Internal Medicine, Etlik Ankara, Turkey JRAAS 2000;1:103. ABSTRACTInfluence of losartan on left ventricular mass and plasma leptin levels in primary hypertension
1Sönmez A., 2Barçin C. 1Uçkaya G., 1Koç B., 1Eyileten T., 1Oktenli Ç., 2Uzun M., 1Kocabalkan F.
Gülhane Medical Faculty, Departments of 1Internal Medicine and 2Cardiology, Etlik Ankara, Turkey JRAAS 2000;1:103. ABSTRACTIntra-individual responses to blockade of the renin-angiotensin system by an ACE inhibitor (lisinopril) and an angiotensin receptor antagonist (candesartan)
P Sever
Imperial College School of Medicine, NHLI Division, Dept. of Clinical Pharmacology, St Mary`s Hospital, London W2, UK JRAAS 2000;1:104. ABSTRACTComparison of candesartan cilexetil 16 mg alone and in combination with hydrochlorothiazide 12.5 mg for the treatment of hypertension
Dr R F Schafers
University of Essen, Essen, Germany JRAAS 2000;1:104. ABSTRACTBioavailability of commercially available losartan (Cozaar®) is not influenced by encapsulation
LG Nilsson and A Lönnebo, Quintiles AB, Sweden JRAAS 2000;1:104. ABSTRACTA Placebo Controlled Comparison Between Candesartan Cilexetil 8mg and Losartan 50mg Monotherapy in Patients with Essential Hypertension Using 36H Ambulatory Blood Pressure Monitoring
JM Mallion, JP Siche, S Mouret, I-L Quessada, JP Baguet
Grenoble University Hospital, France JRAAS 2000;1:104. ABSTRACTThe candesartan cilexetil/HCT combination tablet has a greater and more persistent antihypertensive effect than losartan/HCT in moderate to severe hypertension.
W.Koenig, University Ulm, Medical Center, Ulm, Germany JRAAS 2000;1:105.
|
|
